Navigation Links
Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
Date:4/1/2013

CARLSBAD, Calif., April 1, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of new data in the journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III) resulted in significant reductions in apoC-III and triglycerides, each an independent risk factor for cardiovascular disease.  Hypertriglyceridemia is a serious medical condition associated with premature coronary artery disease and an increased risk for pancreatitis.  Isis is developing its antisense apoC-III inhibitor, ISIS-APOCIIIRx, for the treatment of patients with severe hypertriglyceridemia and plans to report top-line data in the middle of this year. 

"Patients with high triglycerides and high apoC-III levels are at significant risk of developing cardiovascular disease, metabolic syndrome, diabetes and pancreatitis.  Despite currently available triglyceride-lowering agents, many patients cannot reduce their triglycerides to acceptable levels.  Because apoC-III is a key regulator of triglyceride clearance from the blood and itself is an independent risk factor for cardiovascular disease, lowering both apoC-III and triglycerides could provide significant therapeutic benefit," said Richard Geary , Ph.D., senior vice president of development at Isis.  "In this paper, we report consistent activity of antisense inhibition of apoC-III to lower both apoC-III and triglycerides in multiple rodent models of dyslipidemia, in non-human primates and in man.  These data support the potential therapeutic benefit a selective apoC-III inhibitor could offer patients with hypertriglyceridemia an
'/>"/>

SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
2. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
3. MD+DI, the Global MedTech Authority, Publishes One-of-a-Kind Study with ITG Market Research on the Medical Device Outsourcing Landscape
4. Specialty Pharmacy Association of America (SPAARx) Publishes Definition of Specialty Pharmacy
5. Camfil Farr Publishes FAQ on HEPA Air Filters
6. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
9. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
10. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
11. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
(Date:7/28/2014)... and LONDON , July 28, 2014 ... to create and commercialize companion diagnostic using genomic data ...  for non-small cell lung cancer patients  New ... test and is planned to run on Rotor-Gene Q, member of ... enabled by AstraZeneca master framework agreement adds to QIAGEN,s ...
(Date:7/28/2014)... England , July 28, 2014 ... is investing £2.5 million to help it meet ... consumer goods, healthcare, pharmaceuticals and logistics. Albion joins ... ) Over the past 18 ... in its platform, its management team and its ...
Breaking Medicine Technology:ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6OmPrompt Funded for Customer Automation Management Market Expansion 2
... WOODLANDS, Texas, Dec. 5 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... in a Phase 2a clinical trial with LX6171, ... impairment associated with disorders such as,Alzheimer,s disease, schizophrenia, ... will assess the bioavailability of a new oral-suspension,formulation ...
... ulcerative colitis patients, AVENTURA, Fla., Dec. 5 ... that Asacol, an oral, non-steroidal medication that belongs,to ... (5-ASAs), is an,effective and well-tolerated treatment for patients ... proctitis. The results showed,that patients with isolated proctitis ...
Cached Medicine Technology:Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 2Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 3Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 4Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis 2Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis 3Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis 4Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis 5
(Date:7/28/2014)... July 28, 2014 Humility of Mary Health ... 20 at St. Elizabeth Boardman Health Center, 8401 Market St., ... provides information about more than 200 common health problems as ... preventing illness and injury, and advice on when to seek ... a.m. to noon, the evening session runs from 5:30 to ...
(Date:7/28/2014)... 2014 For those with dust allergies, home ... dust allergies—commonly settle in mattresses, bedding, and upholstered furniture and ... mites are microscopic insects that feed on the dead skin ... to keep a million dust mites fat and happy. When ... microscope, the decaying bodies and feces of dust mites can ...
(Date:7/28/2014)... July 28, 2014 Scientists in Japan ... an improved blood test for the asbestos cancer mesothelioma. ... new research. Click here to read it now. ... at Tokyo’s Juntendo University Graduate School of Medicine say ... is a step above the old test. , ...
(Date:7/28/2014)... 2014 Maternal and Family Health Services ... which will be presented at the agency’s 43rd Annual ... at the Westmoreland Club in Wilkes-Barre. , The late ... long-time employee of MFHS. She dedicated her life ... health advocate, and champion for women, children and families ...
(Date:7/28/2014)... new study has found that following a healthy lifestyle ... metabolic syndrome. Published early online in CANCER , ... findings indicate that children with cancer and adults who ... about how their lifestyle may influence their long-term health. ... known to be at increased risk for the metabolic ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2
... Pa., Jan. 15 Today marked the launch ... http://www.nabita.org ). NaBITA,s mission: The National Behavioral ... education, development and support to professionals in schools ... to make their campuses and workplaces safer through ...
... 15 Eli Lilly and Company,(NYSE: ... resolution with the United,States Attorney for the Eastern ... Litigation of the Department of Justice regarding the,previously-reported ... promotional practices for the antipsychotic medication,Zyprexa(R) (olanzapine). , ...
... of the revolutionary MyFluVaccine program launches new website as it ... ... (Vocus) January 15, 2009 -- FFF Enterprises, the nation’s largest ... critical-care biopharmaceuticals announced today the unveiling of its new and ...
... Valley Hospital chooses IVANS LIME, impressed with quick turnaround time and ... ... 15, 2009 -- IVANS , the leading provider of corporate ... choosing high-speed Internet technology over dial-up to access Medicare as they ...
... January 15 Essilor,International announced today that its ... share purchase agreement whereby it has offered to ... of ophthalmic lenses. The,agreement is subject to certain ... Signet Armorlite,s main host,countries. The acquisition is expected ...
... great friend to The Brain Tumor Foundation lost his battle ... surrounded by his family.David fought his illness with courage and ... website, 38lemon.com , he shared his personal battle and ... cancer. So named because of his diagnosis of a ...
Cached Medicine News:Health News:Preventing the Next Virginia Tech -- The National Behavioral Intervention Team Association Launched Today 2Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 2Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 3Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 4Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 5Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 6Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 7Health News:FFF Enterprises Launches New MyFluVaccine Website 2Health News:FFF Enterprises Launches New MyFluVaccine Website 3Health News:Healthcare Providers Choosing IVANS High-Speed Technology to Succeed Within Medicare Modernization Era 2Health News:Healthcare Providers Choosing IVANS High-Speed Technology to Succeed Within Medicare Modernization Era 3Health News:Essilor Agrees to Acquire Signet Armorlite 2
Shahinian lachrymal cannula, blunt tapered with side port....
Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
Button Tip Manipulator, 0.50 mm diameter button tip, angled 45 degrees, 15 mm from tip to bend....
Round serrated handle, polished finish, overall length 130 mm....
Medicine Products: